Osiris Therapeutics is owned by Smith & Nephew, a global medical technology company.
Understanding the Ownership
Smith & Nephew, a well-established leader in medical technology, acquired Osiris Therapeutics in 2019. This acquisition solidified Osiris Therapeutics' position as a key part of Smith & Nephew's Advanced Wound Management and Orthopaedics franchises. As such, Osiris Therapeutics now operates as a subsidiary under the larger Smith & Nephew corporate umbrella.
The acquisition brought together Smith & Nephew's extensive global reach and commercial capabilities with Osiris's innovative regenerative medicine portfolio, particularly its biologic products used in wound care and orthopedics.
About Smith & Nephew
Smith & Nephew is a British-based multinational medical equipment manufacturing company headquartered in Watford, England. Founded in 1856, it is one of the world's largest manufacturers of advanced medical devices and products.
Their core business areas include:
- Orthopaedics: Offering products for joint reconstruction, trauma, and extremities.
- Sports Medicine & ENT (Ear, Nose & Throat): Providing surgical solutions for soft tissue repair.
- Advanced Wound Management: Developing products for chronic and acute wounds, including foams, films, gels, and biologics.
Smith & Nephew is committed to improving patient outcomes through pioneering medical technologies and solutions. You can learn more about their global operations and product offerings on the official Smith & Nephew website.
About Osiris Therapeutics
Osiris Therapeutics is a pioneer in regenerative medicine, focusing on developing and commercializing innovative products for wound care, orthopedics, and other medical applications. Prior to its acquisition by Smith & Nephew, Osiris was known for being the first company to receive FDA approval for a stem cell drug.
Under Smith & Nephew, Osiris's products continue to play a crucial role, especially within the Advanced Wound Management portfolio. Key areas of focus for Osiris Therapeutics products include:
- Diabetic Foot Ulcers: Advanced therapies designed to aid in the healing of chronic wounds.
- Venous Leg Ulcers: Solutions for slow-to-heal leg wounds.
- Surgical Reconstruction: Products used to support tissue regeneration and repair in orthopedic and other surgical procedures.
The integration into Smith & Nephew has allowed Osiris's advanced biologic products to reach a broader market, further enhancing their impact on patient care.
Ownership Summary:
| Parent Organization | Subsidiary Company | Primary Industry Focus | Acquisition Year |
|---|---|---|---|
| Smith & Nephew Plc | Osiris Therapeutics, Inc. | Medical Technology, Regenerative Medicine | 2019 |
